Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage (Q24199107)

3

object named as

Gabriel JE Rinkel

0 references

Merih I. Baharoglu

1

object named as

Merih I Baharoglu

0 references

author name string

Menno R Germans

2

0 references

Marinus Vermeulen

5

0 references

Jan van Gijn

6

0 references

Yvo BWEM Roos

Cochrane Database of Systematic Reviews

7

0 references

publication date

30 August 2013

0 references

published in

0 references

cites work

Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: A double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Anti-fibrinolytic treatment in the pre-operative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the Cooperative Aneurysm Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Intracranial Aneurysms and Subarachnoid Hemorrhage. A Cooperative Study. Antifibrinolytic Therapy in Recent Onset Subarachnoid Hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Best evidence topic report. Antifibrinolytics for the initial management of sub arachnoid haemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic treatment in subarachnoid haemorrhage: present state

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Fibrinolysis in subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Short-term antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: effects on rehemorrhage, cerebral ischemia, and hydrocephalus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic agents in subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Treatment of intracranial aneurysms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy in subarachnoid hemorrhage caused by ruptured intracranial aneurysm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Medical management of patients with aneurysmal subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Subarachnoid haemorrhage: diagnosis, causes and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

21 January 2018

Subarachnoid haemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Do antifibrinolytic agents prevent rebleeding after rupture of a cerebral aneurysm? A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Subarachnoid haemorrhage: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Subarachnoid hemorrhage: an update of pathogenesis, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Systematic review of antifibrinolytic treatment in aneurysmal subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic Treatment in Subarachnoid Hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage. A report of the cooperative aneurysm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Antifibrinolytics in aneurysmal subarachnoid hemorrhage. Do they have a role? Maybe

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Antifibrinolytics in subarachnoid hemorrhage. Do they have a role? No

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Prolonged antifibrinolysis: an effective non-surgical treatment for ruptured intracranial aneurysms?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Tranexamic acid in subarachnoid hemorrhage. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Management of aneurysmal subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Spectrophotometric analysis of CSF after subarachnoid hemorrhage: limitations in the diagnosis of rebleeding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Antifibrinolytic therapy in patients with aneurysmal subarachnoid haemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Natural history of subarachnoid hemorrhage, intracranial aneurysms and arteriovenous malformations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021

Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001245.PUB2

7 January 2021